Clinical Characteristic | Moreno Cohort (FFPE) | TCGA Cohort (RP) |
---|---|---|
Gleason Score | No. of patients (%) | No. of patients (%) |
ā¤ 6 (3ā+ā3) | 11 (11.00%) | 37 (8.75%) |
7 (3ā+ā4) | 53 (53.00%) | 162 (38.30%) |
7 (4ā+ā3) | 22 (22.00%) | 101 (23.88%) |
ā„ 8 | 14 (14.00%) | 158 (37.35%) |
Pathological Stage | ||
āpT2 | 69 (69.00%) | 169 (39.95%) |
āpT3 | 2 (2.00%) | 0 (0.00%) |
āpT3a | 6 (6.00%) | 138 (32.62%) |
āpT3b | 9 (9.00%) | 104 (24.59%) |
āpT4 | 1 (1.00%) | 6 (1.42%) |
Lymph Node Invasion | ||
āPresent | 0 (0%) | 60 (14.18%) |
āAbsent | 37 (37.00%) | 331 (78.25%) |
Surgical Margins | ||
āPositive | 39 (39.00%) | 116 (27.42%) |
āNegative | 56 (56.00%) | 312 (73.76%) |
Age | ||
āMedian | 61.7 | 61 |
āRange | 43.0ā78.0 | 41.0ā77.0 |
Pre-operative PSA (ng/uL) | ||
āMedian | 7.2 | 7.5 |
āRange | 1.8ā72.6 | 0.7ā107 |
Biochemical Recurrence | ||
āNumber of recurrences | 49 (49.00%) | 43 (10.17%) |
āAverage follow-up time in years (range) | 5.79 (0.06ā15.26) | 3.07 (0.06ā13.76) |
Total | 100 | 423 |